Suven Life Sciences, a biopharmaceutical company, witnessed a rise in share price on Friday after it has been granted one product patent from Australia, Europe, Hong Kong, Israel, Norway corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases.

Shares of the company are trading at Rs 309.10, up Rs 8.9, or 2.96% at the Bombay Stock Exchange (BSE) on Friday at 10:25 a.m.

The scrip has touched an intra-day high of Rs 313.80 and low of Rs 294.40. The total volume of shares traded at the BSE is 299,375.